Tackling Tolerability in Obesity Drug Development

• Selective Amylin receptor agonists -does it matter?
• Developing a drug that is highly selective for amylin receptors
• Discussing the future for selective amylin

Speakers:

Jacob Jeppesen

Chief Scientific Officer & Head of Research & Development

Alveus Therapeutics